BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1526691)

  • 1. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S37-43. PubMed ID: 1601530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size.
    Steinijans VW; Hauck WW; Diletti E; Hauschke D; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):571-5. PubMed ID: 1473872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two one-sided tests procedure for assessment of individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S63-8. PubMed ID: 1601534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple formula for sample size calculation in equivalence studies.
    Zhang P
    J Biopharm Stat; 2003 Aug; 13(3):529-38. PubMed ID: 12921399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some issues in the design and interpretation of 'negative' clinical studies.
    Makuch RW; Johnson MF
    Arch Intern Med; 1986 May; 146(5):986-9. PubMed ID: 3963987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalence tests for interchangeability based on two one-sided probabilities.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential equivalence testing and repeated confidence intervals, with applications to normal and binary responses.
    Jennison C; Turnbull BW
    Biometrics; 1993 Mar; 49(1):31-43. PubMed ID: 8513110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferiority trials: the 'at least as good as' criterion.
    Laster LL; Johnson MF
    Stat Med; 2003 Jan; 22(2):187-200. PubMed ID: 12520556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.